Regulation of glioblastoma multiforme stem-like cells by inhibitor of DNA binding proteins and oligodendroglial lineage-associated transcription factors

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1028-1037

  Wu, Yanjue ^a   Richard, Jean Philippe ^b   Wang, Shervin D ^a   Rath, Prakash ^a   Laterra, John ^a,b   Xia, Shuli ^a,b  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 4; NESTIN; OLIGODENDROGLIAL LINEAGE ASSOCIATED TRANSCRIPTION FACTOR 1; OLIGODENDROGLIAL LINEAGE ASSOCIATED TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GALACTOSYLCERAMIDASE; GLIOBLASTOMA; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 2; INHIBITOR OF DIFFERENTIATION PROTEINS; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUBULIN;

EID: 84861693259     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02260.x     Document Type: Article

References (55)

1. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 2010; 5: 14-27.
2. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells: perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
3. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006; 6: 425-36.
4. Pilkington GJ. Cancer stem cells in the mammalian central nervous system. Cell Prolif 2005; 38: 423-33.
5. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193-206.
6. Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-83.
7. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-21.
8. Rath P, Miller DC, Litofsky NS et al. Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma. Exp Mol Pathol 2011; 90: 179-88.
9. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 7267-73.
10. Beier D, Hau P, Proescholdt M et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-5.
11. Corti S, Locatelli F, Papadimitriou D et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006; 24: 975-85.
12. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
13. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
14. Sell S. Potential gene therapy strategies for cancer stem cells. Curr Gene Ther 2006; 6: 579-91.
15. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-5.
16. Sun P, Xia S, Lal B et al. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 2009; 27: 1473-86.
17. Ying M, Wang S, Sang Y et al. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene 2011; 30: 3454-67.
18. Ying M, Sang Y, Li Y et al. KLF9, A differentiation-associated transcription factor, suppresses Notch1 Signaling and inhibits glioblastoma-initiating stem cells. Stem Cells 2010; 29: 20-31.
19. Fritzsch B, Eberl DF, Beisel KW. The role of bHLH genes in ear development and evolution: revisiting a 10-year-old hypothesis. Cell Mol Life Sci 2010; 67: 3089-99.
20. Benezra R. Role of Id proteins in embryonic and tumor angiogenesis. Trends Cardiovasc Med 2001; 11: 237-41.
21. Benezra R. The Id proteins: targets for inhibiting tumor cells and their blood supply. Biochim Biophysica Acta 2001; 1551: F39-47.
22. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001; 20: 8334-41.
23. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990; 61: 49-59.
24. Samanta J, Kessler JA. Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. Development 2004; 131: 4131-42.
25. Ligon KL, Huillard E, Mehta S et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007; 53: 503-17.
26. Lu QR, Sun T, Zhu Z et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 2002; 109: 75-86.
27. Marie Y, Sanson M, Mokhtari K et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet, 2001; 358: 298-300.
28. Azzarelli B, Miravalle L, Vidal R. Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors. J Neuropathol Exp Neurol 2004; 63: 170-9.
29. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001; 20: 8326-33.
30. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005; 5: 603-14.
31. Roberts EC, Deed RW, Inoue T, Norton JD, Sharrocks AD. Id helix-loop-helix proteins antagonize pax transcription factor activity by inhibiting DNA binding. Mol Cell Biol 2001; 21: 524-33.
32. Iavarone A, King ER, Dai XM, Leone G, Stanley ER, Lasorella A. Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature 2004; 432: 1040-5.
33. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosom Cancer 2004; 39: 29-36.
34. Reznik TE, Sang Y, Ma Y et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 2008; 6: 139-50.
35. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
36. Matsui W, Wang Q, Barber JP et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-7.
37. Li Y, Li A, Glas M et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A 2011; 108: 9951-6.
38. Fan X, Khaki L, Zhu TS et al. Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28: 5-16.
39. Kondo T, Raff M. The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J 2000; 19: 1998-2007.
40. Mizuguchi R, Sugimori M, Takebayashi H et al. Combinatorial roles of olig2 and neurogenin2 in the coordinated induction of pan-neuronal and subtype-specific properties of motoneurons. Neuron 2001; 31: 757-71.
41. Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T. Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. Stem Cells 2011; 29: 590-9.
42. Liu C, Sage JC, Miller MR et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011; 146: 209-21.
43. Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007; 25: 2524-33.
44. Fan X, Khaki L, Zhu TS et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28: 5-16.
45. Zhou Q, Anderson DJ. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell 2002; 109: 61-73.
46. Zhou Q, Wang S, Anderson DJ. Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 2000; 25: 331-43.
47. Wang S, Sdrulla A, Johnson JE, Yokota Y, Barres BA. A role for the helix-loop-helix protein Id2 in the control of oligodendrocyte development. Neuron 2001; 29: 603-14.
48. Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 2000; 123: 105-15.
49. Carlson ME, Conboy IM. Regulating the Notch pathway in embryonic, adult and old stem cells. Curr Opin Pharmacol 2007; 7: 303-9.
50. Piccirillo SG, Vescovi AL. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 2006; 5: 59-81.
51. Tzeng SF. Inhibitors of DNA binding in neural cell proliferation and differentiation. Neurochem Res 2003; 28: 45-52.
52. Wong YC, Wang X, Ling MT. Id-1 expression and cell survival. Apoptosis 2004; 9: 279-89.
53. Jankovic V, Ciarrocchi A, Boccuni P, DeBlasio T, Benezra R, Nimer SD. Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc Natl Acad Sci USA 2007; 104: 1260-5.
54. Nagel S, Venturini L, Marquez VE et al. Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Mol Cancer 2010; 9: 151.
55. Sell S. Cancer stem cells and differentiation therapy. Tumour Biol 2006; 27: 59-70.